Literature DB >> 10023719

The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data.

F G Davis1, B J McCarthy, S Freels, V Kupelian, M L Bondy.   

Abstract

BACKGROUND: Five-year survival estimates in standard cancer reports provide a general description of disease outcome that is useful for surveillance and comparison purposes. However, for cancer survivors these overall survival rates may be discouraging, and the relevant question regarding an individual is this: Once he or she has survived for a specified period of time, what is the probability of survival over the next period of time?
METHODS: To address this, conditional survival rates by histology for malignant brain tumor survivors were estimated using the SEER public use data and the Portable Survival System, with 19,105 brain and other nervous system patients diagnosed between 1979 and 1993. Given that the survival curve declines more rapidly in the first 2 years than in subsequent years, conditional probabilities of surviving 5 years given survival to 2 years and 95% confidence intervals (CIs)were calculated. As age is a strong prognostic factor for these tumors, conditional probabilities were also estimated by categories of age.
RESULTS: Estimated 2- and 5-year relative survival rates for patients with malignant brain and other CNS tumors were 36.2% and 27.6%; however, the conditional probability of surviving to 5 years, given survival to 2 years, reaches 76.2% (95% CI: 74.8-77.6). Conditional probabilities varied by histology and age at diagnosis. The conditional probability of surviving 5 years after surviving 2 years was 67.8% (95% CI: 62.6-73.1) for patients with anaplastic astrocytomas, 36.4% (95% CI: 31.9-41.6) for patients with glioblastomas, and 79.8% (95% CI:75.3-84.1) for patients with medulloblastomas.
CONCLUSIONS: Conditional probabilities provide important and encouraging information for those who are brain tumor survivors. The utility of these estimates for other time intervals and other cancers or diseases should be considered.

Entities:  

Mesh:

Year:  1999        PMID: 10023719

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  73 in total

1.  The conditional survival statistics for survivors with primary supratentorial astrocytic tumors.

Authors:  S L Hwang; Y H Yang; A S Lieu; M C Chuang; S J Chang; Y Y Chang; H J Lin; S L Howng
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

2.  Conditional survival among cancer patients in the United States.

Authors:  Ray M Merrill; Bradley D Hunter
Journal:  Oncologist       Date:  2010-07-20

3.  PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.

Authors:  Hongbo Chen; Lin Mei; Lanzhen Zhou; Xiaomeng Shen; Caiping Guo; Yi Zheng; Huijun Zhu; Yongqiang Zhu; Laiqiang Huang
Journal:  J Neurooncol       Date:  2010-12-29       Impact factor: 4.130

4.  Racial/ethnic differences in survival among elderly patients with a primary glioblastoma.

Authors:  Jill S Barnholtz-Sloan; John L Maldonado; Vonetta L Williams; William T Curry; Elizabeth A Rodkey; Frederick G Barker; Andrew E Sloan
Journal:  J Neurooncol       Date:  2007-05-26       Impact factor: 4.130

5.  Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000-2008.

Authors:  Y Yuan; J Ross; Q Shi; F G Davis
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

6.  Pleiotropic role for MYCN in medulloblastoma.

Authors:  Fredrik J Swartling; Matthew R Grimmer; Christopher S Hackett; Paul A Northcott; Qi-Wen Fan; David D Goldenberg; Jasmine Lau; Selma Masic; Kim Nguyen; Slava Yakovenko; Xiao-Ning Zhe; Heather C Flynn Gilmer; Rodney Collins; Mai Nagaoka; Joanna J Phillips; Robert B Jenkins; Tarik Tihan; Scott R Vandenberg; C David James; Kohichi Tanaka; Michael D Taylor; William A Weiss; Louis Chesler
Journal:  Genes Dev       Date:  2010-05-15       Impact factor: 11.361

7.  Dual-mode IVUS catheter for intracranial image-guided hyperthermia: feasibility study.

Authors:  Carl D Herickhoff; Gerald A Grant; Gavin W Britz; Stephen W Smith
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2010-11       Impact factor: 2.725

8.  Conditional survival in gastric cancer: a SEER database analysis.

Authors:  Samuel J Wang; Rachel Emery; Clifton D Fuller; Jong-Sung Kim; Dean F Sittig; Charles R Thomas
Journal:  Gastric Cancer       Date:  2007-09-26       Impact factor: 7.370

9.  Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy.

Authors:  Ze-Shun Zhang; Jing Wang; You-Bi Shen; Cheng-Cheng Guo; K E Sai; Fu-Rong Chen; Xin Mei; F U Han; Zhong-Ping Chen
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

10.  Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.

Authors:  Mairéad G McNamara; Zarnie Lwin; Haiyan Jiang; Caroline Chung; Barbara-Ann Millar; Arjun Sahgal; Normand Laperriere; Warren P Mason
Journal:  J Neurooncol       Date:  2014-01-29       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.